Video

Dr. Grunberg Describes the MASCC International Symposium

Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.

Steven M. Grunberg, MD, Division of Hematology/Oncology, Vermont Cancer Center, Professor of Medicine and Pharmacology, University of Vermont, describes the 2012 Multinational Association of Supportive Care in Cancer (MASCC) Symposium, held in New York City, from June 28-30.

MASCC is an international organization that represents over 50 countries, Grunberg explains. The latest installment of its annual symposium hosted over 1,500 supportive care specialists from 60 countries all with an interest in symptom management, supportive care in cancer, and treating the side effects of both the cancer and its treatment.

Grunberg notes that the ultimate goal of the supportive care specialist is to help make treatments tolerable for patients. The annual MASCC symposium seeks to meet this need by offering 16 study groups, workshops, and multiple international experts specializing in cancer related nausea, vomiting, bone health, mucositis, nutrition, palliative care, and survivorship.

While a majority of the attendees are primarily doctors, approximately one third consists of nurses, psychologists and chaplains. This unique audience provides an opportunity to gain the perspective of a multidisciplinary group. Additionally, the international nature of the symposium provides an opportunity to communicate with colleagues from around the world.

To fully engage its international audience, the MASCC conference is designed to move from continent to continent each year. As a result, the 2013 meeting will be held in Europe.

<<<

View more from the 2012 MASCC International Symposium

Related Videos
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy